Skip to main content
Premium Trial:

Request an Annual Quote

Gene Therapy Treats Alcohol Use Disorder in Animal Model

A gene therapy could potentially treat severe alcohol use disorder, according to a new study in non-human primates appearing in Nature Medicine. In the treatment, an adeno-associated viral vector carrying the gene encoding glial-derived neurotrophic factor, or GDNF, is implanted in the brain — repeated ethanol use affects dopaminergic signaling, leading to a decrease in dopamine release — and this appears to reset the dopamine reward pathway. In their study, researchers from Oregon Health & Science University and elsewhere treated four rhesus macaque monkeys that were a model of alcohol use disorder with this therapy to find that their ethanol consumption dropped by 90 percent. "The monkeys that were treated with this gene permanently started overexpressing dopamine and they decreased their drinking substantially," co-senior author Kathleen Grant from OHSU says in a statement. She and her colleagues note that as the treatment involves surgery and permanently alters the brain, it would only be appropriate to use it to treat severe cases of alcohol use disorder.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.